Australia’s Therapeutic Goods Administration made a surprise move when it reclassified two psychedelic substances as controlled medicines, opening a path for psychiatrists to legally prescribe psilocybin and MDMA to patients with specific treatment-resistant mental illnesses. No other country had taken this regulatory step before.
At a glance
- Psilocybin approval: The active compound in magic mushrooms is now approved as a Schedule 8 controlled medicine for treatment-resistant depression, prescribable by TGA-authorized psychiatrists.
- MDMA therapy: MDMA is approved under the same controlled framework for post-traumatic stress disorder — conditions the TGA described as having few effective alternatives currently available.
- Prescriber controls: Psychiatrists must first be approved through the TGA’s authorized prescriber scheme before they can legally supply these medicines, which remain prohibited for all other uses.
Why the TGA acted
The decision came after the TGA reviewed thousands of written public submissions from patients, researchers, and clinicians. The agency said the volume of responses was “a reasonable indicator of the scope and gravity of the issues for individual and public health.”
Central to the ruling was a November 2022 C.E. study published in the New England Journal of Medicine on single-dose psilocybin use, which the TGA said had further strengthened “the already promising body of evidence” for the substance’s efficacy in treatment-resistant depression. The agency concluded that benefits to patients, combined with tight controls, outweighed the risks.
Post-traumatic stress disorder and treatment-resistant depression share a grim feature: patients with these diagnoses often face a lifetime of medication with limited relief. As Associate Professor David Caldicott, an emergency medicine physician who advocated for psychedelic therapies at Australia’s Royal Commission into Defence and Veteran Suicide, put it: “The conditions for which these drugs might be used are currently conditions for which you’re basically destined to a lifetime of drug use. Whereas the MDMA particularly is used to facilitate psychotherapy, only for a few doses.”
A long and politically complicated history
MDMA was first developed by a pharmaceutical company in the early 20th century C.E. and was used by some psychiatrists during the late 1970s and early 1980s C.E. Political pressure, not scientific evidence, ended that era. The drug was banned in the United States in 1985 C.E. after recreational use expanded, halting clinical research for decades.
Caldicott noted that opposition to MDMA in therapeutic settings had long been a question of politics rather than science — a pattern that made Australia’s willingness to move forward genuinely notable. Stephen Bright, director of the Psychedelic Research in Science and Medicine charity, called it unexpected. “It was unexpected given that Australia is such a conservative country,” he said.
Cautious optimism from researchers
Not everyone in the research community welcomed the speed of the decision. Professor Susan Rossell, a cognitive neuropsychologist who led Australia’s largest psilocybin trial for treatment-resistant depression, urged caution. “These treatments are not well established at all for a sufficient level of broad-scale implementation,” she said. “We’ve got no data on long-term outcomes at all, so that worries me a lot.”
Bright echoed the uncertainty around implementation. At the time of the announcement, no approved products containing psilocybin or MDMA existed on the Australian market, meaning psychiatrists would need to access and legally supply unapproved medicines. Training for practitioners who could actually administer the treatments was also thin on the ground. “There are no products available,” Bright said, “and aside from myself and a handful of colleagues, there’s no-one trained to provide the treatment.”
Those gaps reflect the broader truth about where psychedelic medicine stands globally: the science is promising, but clinical infrastructure, long-term outcome data, and regulatory frameworks are still catching up. Australia’s move creates an opening — it does not, by itself, create a functioning system.
What comes next
The rescheduling took effect from July 2023 C.E. Psychiatrists who want to prescribe must first be approved through the TGA’s authorized prescriber scheme. The substances remain Schedule 9 prohibited drugs for all other purposes — recreational use carries no new protections.
What Australia has done is give researchers and clinicians a legal framework to build from. Patients who have cycled through every available treatment for PTSD or depression without relief now have a pathway — narrow, controlled, and still developing — that did not exist before. That is a meaningful starting point, even if it is only a starting point.
Read more
For more on this story, see: Sydney Morning Herald
For more from Good News for Humankind, see:
- U.K. cancer death rates fall to their lowest level on record
- Marie-Louise Eta becomes the first female head coach in men’s top-flight European football
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
